TXG
10X Genomics
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 10.31B; Volume: 430.57K; AvgVol 3m: 720.99K; Beta: –;
Cost estimate:
P/E: –; EPS: -0.80; EPS growth quarter/prev quarter: -250.10%;
EPS growth this year: 33.30%; EPS growth past 5 years: ;
EPS ttm: -0.80;
P/S: 56.02; P/B: 34.63; P/Cashflow: 41.43; P/FCF: ;
Sales: 251.32M; Sales growth quarter/prev quarter: -23.10%; Sales growth past 5 years: ;
Profitability:
Gross Margin: 77.20%; Profit Margin: -31.10%; Operating Margin: -31.00%;
ROA – return on assets: -13.20%; ROE – return on equity: -19.00%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 2.30%; Insider Transactions:-71.87%;
Institutional Ownership: 83.30%; Institutional Transactions: 34.78%;
Data update: 07.10.2020.